




L I S A N G A
P R O J E C T



KSPH/LISANGA



EXPOSÉ DES MOTIFS



Achieving and Maintaining Epidemic Control through Comprehensive HIV/AIDS Prevention, Care and Treatment Services in the Kinshasa Region of the Democratic Republic of Congo under the President's Emergency Plan for AIDS Relief (PEPFAR)




Lisanga
Project =
consortium
KSPH-EGPAF



Lisanga =
Together



Duration :
30/09/2021 -
29/09/2026



Location :
Kinshasa, 6
Health Zones,
84 facilities




Project objective:
Build on existing
CDC programs to
contribute to the
achievement of
the 2030 goal of
elimination
through
comprehensive,
high-quality
HIV/AIDS
Prevention, care
and treatment.

PROJECT IMPLEMENTATION PROCESS




Mapping intervention areas






RÉSUMÉ DES RÉSULTATS DE L'ANNÉE 1



FY22 performance across program areas

Indicateurs	Annual Target	Results	Perf
Total personnes dépistées au VIH	140450	134713	96%
Total personnes testées VIH +	6619	6363	96%
Total cas incidents annuels	6321	6330	100%
Total PVVIH sous ARV	30278	30314	100%
Suppression Charge Virale (%)		97%	
Couverture Charge Virale (%)		74%	
Total bénéficiaires des services OEV	7828	7533	96%


SUCCESSES




FY22 performance across program areas

Case's Identification	Treatment initiation and maintaining	Viral Load Suppressed and coverage
- Tested : 134713 - Tested HIV+: 6363 - Yield : 4,7%	- Tested HIV+ : 6363 - Tested HIV+ on ART : 6330 - Link on ART : 99,5% - Current : 30314	- Results documented: 20126 - Results 1000 copies : 19469 - Suppressed: 97% - Coverage : 74%

Testés au VIH par ZS: Performance FY22



Testés VIH+ par ZS






DÉTAILS DES RÉSULTATS DE L'ANNÉE 1

1^{ER} 95 :
CASE'S
FINDING

Trend Testing



Global Yield
4,7 %

HTS_TST Yield
<15 (%)
2.3%


HTS_TST Yield
15+ (%)
5%

HTS_TST Yield
- Females
(%)3.9%


HTS_TST Yield
- Males
(%)6.5%



HTS_POS




Trend Yield by Level






Comment

Trend HIV+ Community Contribution




HTS_POS by age/Level






INDEX TESTING

Index Testing: Contribution to Total Positives 29%








DÉTAILS DES RÉSULTATS DE L'ANNÉE 1


2^e 95 :
Link to
treatment

Trend Link On ART





FY22 performance across program areas

Oct to Dec 2022
* FY22 Results : Linkage to Treatment (%):
98,7



Archievment TX_NEW







Female
Male

Nombre de PVVIH identifiées :
Tendances



KSPH/LISANGA

TX_NEW by HZ Over Time




TX_NEW – Total
6330


TX_NEW - Males
2 819

TX_NEW - Females
3 511

TX_Curr over Time



TX_CURR by Age/sex






DÉTAILS DES RÉSULTATS DE L'ANNÉE 1

3^e 95 :
VL
Suppression


VL Suppressed VS VL Coverage by Site



VL Suppressed
97%

VL Coverage
74%

VL Suppressed VS VL Coverage












SERVICES SPÉCIFIQUES




SERVICES SPÉCIFIQUES

PMTCT

PMTCT



FY22 Results Analytic Visualizations: PMTCT_FO Results



FY22 Results Analytic Visualizations: Pregnant Women Viral Suppression Single Value

Viral Suppression Among Pregnant Women (%)

92.2%

FY22 Results Analytic Visualizations: BF Women Viral Suppression Single Value


Viral Suppression Among Breastfeeding Women (%)

93.6%





SERVICES SPÉCIFIQUES




TB

TB Cascade

Health Zone	TX_CU RR	TX_TB Denom	% Screened	Screened d POS	Specimen sent	Specimen sent positive	TX_TB NUM
Binza Ozone	3550	3236	91%	94	88	27	27
Kimbanseke	4850	4583	94%	35	35	19	19
Kingabwa	5540	5202	94%	81	79	18	18
Masina 1	5762	5171	90%	72	72	35	35
Ngaba	5479	5334	97%	18	18	13	13
Nsele	5133	4953	96%	20	20	16	16
Total Lisanga	30314	28479	94%	320	312	128	128


Type diagnostic tests		
Smear Only	Gene Xpert MTB / R if Assay	Other (No Xpert)
148	53	111




■ Smear Only ■ Gene Xpert MTB / R if Assay ■ Other (No Xpert)

TB/HIV integration

FY22 Results Analytic Visualizations: ART Patients, Screen Positive for TB and TB Treatment



FY22 Results Analytic Visualizations: TB_STAT and ART Cascade



FY22 Results Analytic Visualizations: TB_STAT Coverage (%) Single Value

TB_STAT Coverage (%)

97.4%

FY22 Results Analytic Visualizations: TB_STAT Prevalence (%) Single Value

TB_STAT Prevalence (%)

10.1%





SERVICES SPÉCIFIQUES

KP

KP

FY22 Results Analytic Visualizations: KP Yield Total Single Value

KP HIV Testing Yield (%)

9%

FY22 Results Analytic Visualizations: KP Linkage Total Single Value

KP Proxy Linkage (%)

95.6%


FY22 Results Analytic Visualizations: KP Viral Suppression Total Single Value


KP Viral Suppression (%)

97.8%

FY22 Results Analytic Visualizations: KP Clinical Cascade

Democratic Republic of the Congo








SERVICES SPÉCIFIQUES


OVC

Achievement

<u>Indicators</u>	<u>Targets</u>			<u>Results</u>			<u>Performance</u>		
	<18	> 18	Total	<18	> 18	Total	<18	> 18	Total
COP21 OVC_HIVSTAT	6781		6781	5286	-	5286	78%		78%
COP21 OVC_SERV	6781	1047	7828	5286	2247	7533	78%	215%	96%



OVC_SERV



OVC_HIVSTAT





SERVICES SPÉCIFIQUES

SUPPLY CHAIN



Description of the Supply Chain

- PEPFAR's supply chain is led by USAID through the Global Health Supply Chain (GHSC) which is implemented by several implementing partners.
- Supply chain actors:
 - GHSC
 - LISANGA Project
 - BCZS
 - FOSA
- Roles of the actors:
 - GHSC: Quantification, Purchase and shipment of products, Last mile distribution, Technical assistance
 - LISANGA Project: Technical assistance, Last mile distribution, Reporting
 - BCZS: Last mile distribution, Supervision, Reporting
 - Health facilities: Dispensing, Reporting

Supply Chain Issues

- Discrepancy between deliveries and the beginning of the quarters
- Partial deliveries
- Stock shortages

Addressing supply chain issues

- Bi-weekly call GHSC- DRC partners and backstops to address supply chain issues
- Quarterly collection on cohorts to prepare distribution plans
- Quarterly meeting with all actors to prepare deliveries to site level
- Local purchase by the LISANGA project of rapid test kits to compensate for stock-outs



PERFORMANCES & DÉFIS

Performances

1^{er} 95:

- Atteinte des cibles fixées

2^{ième} 95:

Atteinte des cibles fixées

3^{ième} 95:

Atteinte des cibles fixées

Défis et perspectives (1^{er} 95)



- **1^{er} 95**



- ✓ Contribution non optimale de la porte d'entrée communautaire (40%)
- ✓ Faible proportion des hommes dans la cohorte (37,9%)
- ✓ Faible couverture de l'EID

- Implication des relais communautaires
- Utilisation de l'outil d'évaluation de risque comportemental et d'identification des ménages et des cas suspects
- Dépistage dans le milieu de travail des hommes
- Redynamisation de la stratégie des Mère-Mentors
- Renforcement de la collaboration entre l'équipe OVC, l'équipe clinique et communautaire

Défis et perspectives 3^{ème} 95



Faible couverture de la CV (74%)

Long délai d'attente des résultats de la CV

- Implication des RECO dans le suivi des patients pour le **prélèvement CV**
- Formation des communautaires sur le **prélèvement CV**
- Couplage pour tous les patients les RDV de **prélèvement CV** au retrait ARV
- Contractualisation avec des nouveaux laboratoires pour le **prélèvement CV**



SERVICES SPÉCIFIQUES

FINANCES

KSPH EXPENDITURE REPORT DETAILS - PMS

	PEPFAR	ARPA	TOTAL	
Total Federal funds authorized (a)	5 000000,00	245960,00	5 245 960,00	100%
Drew down from PMS (b)	4 987206,00	245000,00	5 232206,00	99,7%
Balance (c) = (a)-(b)	12 794,00	960,00	13 754,00	0,3%
Expenditure (d)	4 968620,44	228 577,59	5 197 198,03	99,1%
Cash on hand (to be returned to PMS) (e) = (b)-(d)	18 585,56	16 422,41	35 007,97	0,7%
Unobligated balance of federal funds (f) = (c)+(e)	31 379,56	17 382,41	48 761,97	0,9%

ANNÉE 2

